Effects of anthracycine derivatives on hepatic neoplastic nodules of Lewis lung carcinoma and colon adenocarcinoma 26
1991
Effects of Anthracycline Derivatives on Liver Tumors in Mice
Sample size: 67
publication
Evidence: moderate
Author Information
Author(s): M. Iigo, K. Nishikata, Y. Nakajima, A. Hoshi
Primary Institution: National Cancer Center Research Institute
Hypothesis
Which anthracycline derivative is the most active against liver tumors?
Conclusion
ME2303 showed superior antitumor effects compared to other anthracycline derivatives in mice with liver tumors.
Supporting Evidence
- ME2303 cured 5 out of 6 mice with advanced liver tumors.
- More than 50% of mice were cured with ME2303 and pirarubicin.
- Doxorubicin showed limited effectiveness with only 2 out of 6 mice cured.
Takeaway
Researchers tested different cancer drugs on mice with liver tumors, and one drug, ME2303, worked much better than the others.
Methodology
Mice were injected with tumor cells and treated with various anthracycline derivatives to evaluate antitumor effects.
Limitations
The study was conducted on mice, which may not fully represent human responses.
Participant Demographics
Male BDF or CDF mice, weighing 22-24 g.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website